Well that's in bite. a lot Salveen one
Let's see.
for quarter. we view Let that is contractions the means. what already The that will was bounce inventory with it the in million me What up in week can illustrate gave say inventory. fourth back about our approximately. of will saw means AMPYRA A our that a view. said, the that we inventory that start be is to made we fourth the issues of week haven't just inventory say quarter, that reference I $XX The let's
that a need toddle to just of give a how is much reference the point make So we numbers. to up for you do
The quarter. some year we on expect to over there don't that were this into them D&A, the carry piece fourth unusual items second
is question we yeah Now Tozadenant, this. on It's molecule the had second mechanism. I you think obviously had same it the discussed a but was different
they [ph] Japan. You NDA istradefylline they've other were for. recently it Preladenant HKN's approved is going which may you molecule which -- in They that out I to is think are referring announced have drug frankly and is that to an the there submit
it for found extensive trials now that the to to a successful Preladenant that track not review that investigators they're FDA I have here. together. approved it subject successful. JAMA very enough been track serious the and in an Japan. a if post-mortem got the NDA an were And those We put of the in active clinical was Their certain have talking you they and of trials these that other in istradefylline, authors have it go the conduct The Merck persuasive. on record. apparently in the now. record been And the that not been mixed of the fact failure, was relentless won't trial think trial successful there and it based submit Japan molecule been And at conclusion all had have is that was look into with going is flaws. I detail of all There track the record across drugs
the that was account findings Biotie and You issues. send and together the persuasive took paper team design in trial management and the can happy But to from build of that Preladenant were features advisors trial the and of we address oversight their those read all and the put a to impressed into you. we're that those study trial and into it to
how out way but data be, first and we Phase I Now quarter set tozadenant there's is you in any look will will find the compelling don't around think that that. the a say just that if will data it successful I Xb at
on a adjusted there dose four basis. got measures of is essentially evidence a arms dose the You've effect, placebo, clear worked placebo and of different versus all outcome
been So, XXX the the of for you best reduction the X.X class. that's good milligram time plus that hours adjusted off any in drugs dose a this placebo that's of reported margin, had at by best which in is the
it all a we it find X for months exactly is put profile will think how we'll together very we a it So out. out few strong product and obviously a Phase turns in
